Map
GAIA
NK-like cell
platform
A breakthrough in
eliminating solid tumors
A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.
GAIA's antibody-anchoring
and activating peptide
A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors
GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.
Core Technology II
News
-
News
The progress report on the safety and clinical efficacy of GAIA-102 against pediatric solid malignant tumors will be presented at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology
More -
News
At the European Society for Medical Oncology 2024, the interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) will be presented
More -
News
Notice of Adoption of AMED Grant for Development of Production Methods Aimed at Practical Application of Regenerative Medical Products
More -
News
At IMMUNOLOGY 2024, research results about GAIA-102 were presented
More -
News
DLT evaluation of the monotherapy cohort for GAIA-102 in the clinical trial for pediatric patients with relapsed/refractory solid malignancies has been completed
More